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ABSTRACT
Cancer now ranks as the leading cause of death globally, outpacing mortality 
rates for HIV/AIDS, malaria, and tuberculosis combined. Cancers and other non-
communicable diseases (NCDs), in particular, are quietly taking center stage in 
many low- and middle-income countries in sub-Saharan Africa and worldwide, 
and these countries are projected to carry as much as 80 percent or more of the 
global cancer burden by 2030. Yet, there are severe inequities in the response 
to this burden, and many patients diagnosed with cancer are unable to access 
comprehensive cancer care simply because of where they live. In policy and 
advocacy circles, cancer is often seen as too challenging and expensive to treat 
in low resource settings, and funding and priority-setting for cancer has fallen 
substantially behind the current disease burden in sub-Saharan Africa. This is an 
often repeated narrative in global health, with the HIV/AIDS epidemic serving 
as an especially telling example of how inaction can fuel the costly spread of 
disease. However, the global HIV/AIDS response has broken the cycle of inaction 
and achieved impressive successes in expanding access to treatment, even in the 
poorest regions of the world most in need of support. The trajectory of the HIV/
AIDS epidemic in sub-Saharan Africa and its international response can provide 
critical lessons for the future of political advocacy, funding, and treatment 
delivery for cancer in low- and middle-income countries worldwide. This paper 
examines these lessons for cancer in the context of new international agenda-
setting priorities such as the post-2015 Sustainable Development Goals, and 
discusses the feasibility of providing cancer treatment in sub-Saharan Africa.
ACRONYMS
AIDS Acquired Immune Deficiency Syndrome
AORTIC African Organization for Research and Training in Cancer
APCA African Palliative Care Association
ARV Antiretroviral therapy
CANSA Cancer Association of South Africa
DAH Development assistance for health
EBV  Epstein-Barr Virus
EVD Ebola Virus Disease
FCTC Framework Convention on Tobacco Control
Global Fund Global Fund to Fight AIDS, TB, and Malaria
GO Global Oncology, Inc.
GTF.CCC Global Taskforce on Expanded Access to Cancer Care and Control
HIV Human Immunodeficiency Virus
IAEA International Atomic Energy Agency
IARC International Agency for Research on Cancer
IHME Institute for Health Metrics and Evaluation
MDG Millennium Development Goals (2000-2015)
MSF Médecins Sans Frontières
NCDs Non-communicable diseases
NCI National Cancer Institute (United States)
NGO Non-governmental organization
PEPFAR President’s Emergency Plan for AIDS Relief (United States)
SDG Sustainable Development Goals (2015-2030)
TB  Tuberculosis
TPP Trans-Pacific Partnership
UCI  Uganda Cancer Institute
UN United Nations
UNAIDS Joint United Nations Programme on HIV/AIDS
USAID United States Agency for International Development
WHO World Health Organization
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With the outbreak of Ebola virus disease (EVD) in Guinea, Sierra Leone, and Liberia in 2014, the global health community has been reminded of an infectious disease story that we know well. 
Throughout global health and international development, infectious diseases 
and intense, fear-inducing epidemics such as Ebola and HIV/AIDS, have been 
identified as the defining health issue for sub-Saharan Africa and low-income 
countries worldwide. After the first Ebola case was identified in Guinea in March 
2014, the outbreak was initially met with a slow and insufficient response by 
the international community and diagnoses quickly escalated throughout 
countries unequipped to control and treat the virus, resulting in high mortality, 
and further overwhelming already fragile health systems across West Africa 
(Dahn, Mussah, and Nutt 2015, Alexander et al. 2015). By the summer of 2015, 
however, a substantial amount of global investment had been directed towards 
curbing the Ebola epidemic and case rates fell dramatically. Much remains to 
be done, and each of these countries have begun to work with various partners 
on the ongoing challenge of rebuilding health infrastructure in affected 
communities throughout the region (Save the Children 2015). 
Like Ebola, HIV/AIDS highlights this well-known and often repeated narrative 
in global health — the costly spread of deadly epidemics fueled by inaction. But 
HIV/AIDS — and to a certain extent, Ebola — also highlights the impressive 
outcomes that can be realized when appropriate attention is paid, especially in 
neglected regions of the world most in need of support. 
While conventional wisdom within global development consistently places 
infectious diseases such as Ebola and HIV/AIDS at the forefront of funding and 
advocacy efforts in both national and international settings, a story in global 
health that has rarely hit headlines is that of cancer and chronic diseases. A 
pernicious myth exists regarding cancer control in sub-Saharan Africa: in the 
midst of health crises surrounding well-known infectious diseases associated 
with poverty such as HIV/AIDS, Ebola, or malaria, cancer is considered by 
many to be neither a substantial problem in Africa, nor a problem that can be 
effectively addressed in a low-resource setting. Yet, rising burdens in cancer 
and other non-communicable diseases (NCDs) have gone largely overlooked in 
sub-Saharan Africa and the developing world, and these diseases are quickly en 
route to becoming the next overwhelming challenge for international health and 
development in the longer-range future. 
With cancer in particular, the global health community appears to be repeating 
history. Although cancer represents a challenging set of diseases to treat and 
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a difficult patient experience regardless of where a patient might live, where 
a patient might live has a direct impact on whether his or her cancer will be 
treated at all. For many patients in low-income countries throughout sub-
Saharan Africa, even a treatable cancer diagnosis is often a death sentence. In 
the face of myriad competing problems, the global health community has simply 
accepted this fate for millions of cancer patients worldwide. Similar to voices 
that stalled the initial implementation of an HIV/AIDS response in low-income 
regions like sub-Saharan Africa, and consistent with others that questioned 
whether the recent Ebola crisis was one that the international community 
should engage in, some development experts have raised concerns regarding the 
feasibility of a global cancer response; cancer has been deemed too challenging 
to address in low-income countries. Expanding access to cancer treatment, in 
particular, is a mere blip on the vast map of public health priorities in most low-
income countries, especially in sub-Saharan Africa. 
Yet, can lessons from infectious disease responses such as Ebola or the global 
AIDS movement be applied to the medically demanding complexities of care 
across various cancers? Considering the challenging interplay of infectious 
and non-communicable diseases in low-resource settings, how should the 
international development community prioritize prevention and treatment 
programs moving forward? Is there room for an expansion of integrated service 
delivery of cancer care across NCDs and within existing HIV/AIDS and infectious 
disease programs? Where does the experience of a cancer patient in sub-Saharan 
Africa fit within the post-2015 sustainable development goals agenda? 
The paper examines the feasibility of providing cancer treatment in low- and 
middle-income countries in the developing world. In particular, it suggests ways 
in which the global HIV/AIDS movement can inform the future of political 
advocacy, funding, and treatment delivery for cancer in sub-Saharan Africa. 
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CANCER IN SUB-SAHARAN AFRICA:  
DISEASE BURDEN AND EMERGING TRENDS
Empirically, cancer is a challenge for low- and middle-income countries. Cancers cumulatively now rank as the leading cause of death worldwide, outpacing mortality rates for HIV/AIDS, malaria, and tuberculosis 
combined (EIU 2009, Jemal et al. 2014). Low- and middle-income countries 
currently account for slightly more than half of all new cancer cases each year 
(Boyle and Levin 2008) and these countries are projected to carry as much as 
80 percent or more of the global cancer burden by 2030 (Farmer et al. 2010). At 
the same time, only five percent of all global resources being spent on cancer are 
allocated in lower income countries, contributing to severe inequities in cancer 
treatment worldwide (Knaul, Frenk, and Shulman 2011). If current trends 
remain unaddressed, rising rates of cancer will continue to inflict a substantial 
impact on the health and socioeconomic stability of sub-Saharan Africa. 
There are many explanations for upward trends in cancer prevalence in Africa. 
In part, the rising rates of cancer can be explained by the epidemiological 
transition currently taking place in these regions. As many health initiatives 
and programs throughout sub-Saharan Africa have been successful in reducing 
preventable death from infectious diseases such as HIV/AIDS and tuberculosis, 
many Africans are living longer and are more likely to be diagnosed with both 
endemic and emerging non-communicable diseases like cancer (Lingwood et 
al. 2008). Changing lifestyle practices as a result of globalization have also been 
key in terms of transitioning disease burdens (Sasco 2008). Lifestyle risk factors 
such as increased tobacco and alcohol use, sedentary lifestyles, and unhealthy 
diets are common exposures for many priority cancers and will likely be major 
influences in the projected increase in cancer rates in low- and middle-income 
countries over the next few decades (American Cancer Society 2011, Jemal 
et al. 2014). Outdoor air pollution and increased exposure to carcinogenic 
contaminants from occupational risks and increased industrial production 
in urban settings are also expected to be major players in rising cancer rates 
throughout the African continent (NCD Alliance 2012). 
Although increased urbanization and lifestyle-related risk factors may play an 
increasingly substantial role in the cancer narrative in sub-Saharan Africa, these 
pathologies do not entirely account for the disease burden in the developing 
world, especially among poor populations in low-income countries (Bukhman 
and Kidder 2011). In resource-limited settings, often a very different burden of 
disease and risk factor profile is prevalent. For instance, as a recent American 
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Cancer Society Cancer Atlas map illustrates (Figure 1), approximately 33 percent 
of all cancers diagnosed in sub-Saharan Africa were due to infectious agents, a 
percentage substantially larger than many other geographical regions (Jemal et 
al. 2014). Infectious diseases continue to be a leading risk factor for many of the 
most common cancers in low-income populations, resulting in cervical cancer 
diagnoses due to human papilloma virus (HPV) exposure, bladder cancer due 
to complications of schistosomiasis, liver cancer due to untreated hepatitis B 
infection, and Kaposi’s sarcoma and various lymphomas associated with HIV 
(American Cancer Society 2011). Other exposures related to poverty are at play 
as well, such as poorly ventilated indoor cooking stoves resulting in an increased 
risk of lung, nasopharyngeal, and esophageal cancers in populations with 
otherwise low tobacco smoking rates (Gordon et al. 2014). 
Figure 1. Fraction of New Cancer Cases Attributable to Infection in 2008,  
by Region
Source: The Cancer Atlas, Second Edition (Jemal et al. 2014)  
Reprinted by the permission of the American Cancer Society, Inc. All rights reserved
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Because data on cancer is often given as a combined figure, however, these 
projected data points highlighting rising incidence do not adequately illustrate 
the complexities of addressing the multitude of cancers and associated risk 
factors present in the region. As Table 1 demonstrates, health care providers in 
sub-Saharan Africa must be prepared to receive patients with many different 
types of cancers, at very different stages of disease, each carrying different 
risk factors, clinical outcomes, and treatment options (Institute of Medicine 
2007, Jemal et al. 2014). For instance, in 2012, the leading causes of death 
for men diagnosed with cancer in sub-Saharan Africa were prostate, liver, 
Kaposi’s sarcoma, and esophageal cancers (IARC 2012). Prostate cancer is most 
often attributed to genetic predisposition and is difficult to treat, but can be 
detected in early stages through screening interventions. Common risk factors 
for liver cancer include both alcohol use and untreated hepatitis B infection. 
While the etiology and severity of esophageal cancer in African men is not well 
understood, it is often attributed to tobacco use, indoor air pollution, and non-
Table 1. Leading Cause of Cancer Death in Sub-Saharan Africa and Associated 
Risk Factors (2012)
RANK CANCER MORTALITY COMMON RISK FACTORS
1 Cervical 57,381 HPV infection
2 Breast 47,583 Genetic predisposition, reproductive 
patterns, alcohol and tobacco use, obesity, 
environmental contaminants
3 Prostate 37,802 Genetic predisposition, dietary patterns
4 Liver 37,353 Hepatitis B and C, alcohol use, 
schistosomiasis, aflatoxin contamination
5 Kaposi sarcoma 25,352 HIV infection
6 Esophageal 22,373 Dietary patterns, tobacco and alcohol use, 
indoor air pollution
7 Colorectal 21,076 Dietary patterns, obesity
8 Non-Hodgkin 
lymphoma
18,923 Immune deficiency, HIV, malaria, or 
Epstein Barr Virus (EBV) infection
9 Stomach 16,763 H. pylori infection, dietary patterns, 
anemia, tobacco use
10 Lung 14,143 Tobacco use, indoor air pollution
Source: IARC 2013, American Cancer Society 2011
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diverse dietary patterns (American Cancer Society 2011). Kaposi’s sarcoma in 
sub-Saharan Africa has largely been associated with later-stage HIV infection, 
and treatment generally requires availability of chemotherapy, surgery, or 
radiation options (American Cancer Society 2011).
In women, breast and cervical 
cancer are the leading cause of 
cancer deaths in sub-Saharan 
Africa (American Cancer Society 
2011). Cervical cancer can be 
prevented cost-effectively by 
providing HPV vaccinations 
to young women, and early detection programs using tested “see and treat” 
methods are important tools to reduce mortality in settings where treatment is 
available (Sahasrabuddhe et al. 2012). Breast cancer incidence is explained by a 
complicated mix of genetic predisposition, reproductive patterns, and lifestyle 
risk factors and can be difficult to treat at later stages, but like cervical cancer, 
treatment options such as surgery, radiation, and chemotherapy can be effective 
when cases are detected early (Institute of Medicine 2007). 
As a mere subsection of the total cancer burden in sub-Saharan Africa, these six 
diseases alone illustrate the diversity and intricacies that come with addressing 
cancers at the population level. Across the entire cancer spectrum in sub-
Saharan Africa, communities and patients require adequate coverage for not only 
prevention, early screening, and detection services, but also for varied and often 
complicated treatment needs, including surgery and radiation capabilities, drug 
delivery for chemotherapy and adjuvant drugs, as well as palliative care and end-
of-life support (Kingham et al. 2013, Vento 2013). Largely due to the complexity 
of oncology as a medical field and in the context of public health, rising cancer 
rates pose a particularly significant challenge in resource-limited settings. 
…in the context of public health, 
rising cancer rates pose a 
particularly significant challenge 
in resource-limited settings...
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Figure 2. Most Commonly Diagnosed Cancers Per Country in Sub-Saharan 
Africa, Male and Female (2012) 
Source: The Cancer Atlas, Second Edition (Jemal et al. 2014)  
Reprinted by the permission of the American Cancer Society, Inc. All rights reserved
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Emerging trends in cancer incidence in sub-Saharan Africa are even more 
distressing considering that despite the existence of effective, low-cost cancer 
therapy, treatment coverage for cancers is nearly non-existent in many low-
income countries (Kingham et al. 2013). In the years between 2000-2020, 
approximately 10 million patients are estimated to die of cancer in sub-Saharan 
Africa (Kerr, Milburn, and Arbuthnott 2007). Although greater numbers of 
patients are diagnosed with cancer each year in higher income countries, a 
patient diagnosed with cancer in a low-income country is much more likely to 
die of their disease due to a later stage diagnosis, lack of access to treatment, 
and weak health care capacity (Kanavos 2006). Patients in poorer countries 
do not have access to effective community education, preventive services, 
screening and early detection, or adequate primary health care, and thus, tend 
to come to health centers and hospitals with late stage cancer diagnoses that 
are incredibly difficult to treat (American Cancer Society 2011). Often, these 
patients who have the greatest medical 
need have the least access to affordable 
treatment options and are unable to 
receive care (Maher and Ford 2011). 
As is the case with many diseases 
afflicting patients in low- and middle-
income countries, cancer medications 
are rarely provided at discounted rates by the government — thus, patients 
are faced with a choice between purchasing expensive cancer therapies, which 
contribute to catastrophic household health expenditures, or refusing necessary 
treatment due to exorbitant costs of therapy (Sambo et al. 2012). Medicines for 
non-communicable diseases like cancer also tend to require a greater economic 
burden for families due to their chronic or complex nature (Lage 2011). 
Yet, currently, very little funding and policy attention is being directed at 
the emerging burden of cancer and non-communicable diseases in sub-
Saharan Africa (Knaul, Frenk, and Shulman 2011). As infectious diseases 
such as HIV/AIDS and Ebola have consistently demonstrated, the costs of 
inaction for cancer in Africa will be enormous, in terms of both mortality and 
financial sustainability (Knaul et al. 2010). As cancer incidence and mortality 
rates continue to rise throughout the continent, many will struggle with 
the catastrophic costs of treatment and care, more and more people will be 
kept out of work, and poorer families will bear a disproportionate share of 
illness and suffering (Samb et al. 2010). Cancer and other non-communicable 
diseases threaten to exacerbate issues of poverty at the national level as well, 
... a response to cancer will be 
critical for the longer-range 
future of sub-Saharan Africa.
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endangering economic productivity, burdening already fragile health systems, 
and markedly driving up health care costs (World Bank 2011). As a result, cancer 
control in Africa will require a broad, comprehensive response across a multitude 
of risk factors and diseases, ranging from less expensive, simpler interventions 
to more substantial investments in health infrastructure. Ultimately, cancer in 
sub-Saharan Africa reveals the interconnectedness in communicable and non-
communicable disease burden in low-resource settings and the crucial role of 
effective health systems in preventing needless death. 
Encouraging progress in HIV/AIDS and infectious disease control has had 
a substantial impact on the health profile of many low- and middle-income 
countries. However, infectious diseases considered more indicative of regions 
of poverty, such as HIV/AIDS, have not gone away and in some cases, even 
contribute directly to the burden of non-communicable diseases like cancer. 
Cancer, like HIV/AIDS, poses severe health and development threats to already 
limited national budgets and traditional funding and advocacy channels in 
global health (Boyle and Levin 2008). As a result, a response to cancer will be 
critical for the longer-range future of sub-Saharan Africa. 
SETTING AN ADVOCACY EXAMPLE:  
HISTORY OF THE GLOBAL HIV/AIDS RESPONSE
Since the introduction of the HIV virus in the early 1980s, HIV/AIDS rapidly emerged as a devastating public health threat that has frustrated the international community and has decimated the health 
and development of low- and middle-income countries worldwide (El-Sadr, 
Holmes, et al. 2012). While the HIV/AIDS movement in the United States was 
characterized by early activism, attention to the rising global threat of HIV/
AIDS in low-income countries in sub-Saharan Africa was slow to develop 
(El-Sadr, Morrison, et al. 2012). In the early years of the epidemic, HIV/AIDS 
had progressed relatively unchecked in poorer countries and HIV was initially 
met with little to no coordinated, comprehensive response in either national 
or international arenas (Broder 2010). Medically efficacious antiretroviral 
treatment (ARV) had been developed by the early 2000s, but therapy was 
only available at a high cost and many believed cost-effective scale-up of HIV 
programs in low-resource settings to be a pipe dream (Piot, Kazatchkine, et 
al. 2009). The chorus of international development experts echoed a familiar 
refrain: HIV/AIDS was too complicated and too expensive to treat globally, 
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especially in regions like sub-Saharan Africa (El-Sadr, Morrison, et al. 2012). Yet, 
some argued otherwise. For instance, at a Presidential Fellows Lecture to the 
World Bank in November 2003, Peter Piot, then the Executive Director of the 
Joint United Nations Programme on HIV/AIDS (UNAIDS) and Under Secretary-
General of the United Nations, addressed the international community with these 
words about the epidemic: “Act now, or pay later. Africa has learned this lesson 
the hard way. Denial and ignorance do not reverse the epidemic” (Piot 2003). 
From an advocacy standpoint, many momentous events aligned in the 
early 2000s, which helped propel HIV/AIDS in Africa to become a priority 
international development issue and a cause célèbre in global aid efforts. In 
January of 2000, the HIV/AIDS epidemic notably became the first emergency 
health issue addressed by a special session of the United Nations General 
Assembly (Goosby, Dybul, et al. 2012). In addition, the announcement of the 
Millennium Promise initiative in September 2000, operationalized as eight 
Millennium Development Goals (MDGs) expiring in 2015 (Figure 3), was a 
key policy moment for agenda-setting in global health that has had significant 
impacts on development agencies and non-governmental partners worldwide 
(Saith 2006, Kim et al. 2011). Due to the influence of then UN Secretary General 
Kofi Annan, reversing the spread of the HIV/AIDS epidemic became the central 
priority for MDG 6, which was later edited to include malaria, tuberculosis 
(TB), and other parasitic diseases (Hulme 2009). Largely due to the influence of 
the MDGs, HIV/AIDS has quickly emerged as a primary beneficiary of health 
funding and advocacy over the last fifteen years (Saith 2006, Shiffman 2008). 
Figure 3. Millennium Development Goals, 2010-2015 
Source: United Nations 
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Funding for HIV/AIDS, like advocacy, has been propelled into the mainstream 
through the influence of a few groundbreaking aid initiatives. Launched in 
2003 by President George W. Bush, the US Government’s President’s Emergency 
Plan for AIDS Relief (PEPFAR) pledged an initial $15 billion to HIV/AIDS 
programming over five years and has since grown to become the largest bilateral 
aid initiative for a single disease in the developing world (El-Sadr, Holmes, et al. 
2012). PEPFAR drove the global expansion of HIV treatment, and the world has 
changed dramatically for millions of HIV/AIDS patients in low-resource settings 
(El-Sadr, Morrison, et al. 2012). The Global Fund to Fight AIDS, TB, and Malaria, 
founded in 2002, has been another prominent leader in the international 
community (Tan, Upshur, and Ford 2003). The Global Fund exists exclusively 
as a funding agency, receiving funds from aid agencies and private donors 
which are then allocated to governments and non-governmental organizations 
(NGOs) implementing HIV/AIDS programs in low- and middle-income 
countries (Maciocco and Stefanini 2007). UNITAID, a financing mechanism 
that is primarily supported through an international levy on air ticket sales, 
also emerged in the early 2000s, again focusing efforts on extending access to 
medicines and equipment for HIV/AIDS, malaria, and tuberculosis (Atun, Knaul 
et al. 2012). Like PEPFAR and the Global Fund, UNITAID has become one of the 
most innovative and influential development funding platforms currently in 
existence worldwide (Hulme 2009, Atun, Knaul, et al. 2012). 
The global HIV/AIDS response provides one of the strongest, if still imperfect, 
models for supporting the expansion of treatment in low-resource settings. The 
rollout of antiretroviral treatment for HIV in low- and middle-income countries 
has resulted in substantial policy shifts in various arenas related to access to 
medicines, including in the pharmaceutical industry, international trade law, drug 
delivery systems, and health system infrastructure. The production of generic 
antiretroviral medications has dramatically reduced the cost of HIV treatment 
and substantially improved affordability for patients in low-resource settings 
(Maher, Ford, and Unwin 2012). In 2012, approximately 9.7 million patients 
worldwide received antiretroviral therapy for HIV, and the global percentage 
of patients covered by treatment continues to rise (UNAIDS 2013a). As HIV 
medications have become more available and more affordable in the developing 
world, HIV/AIDS has transitioned from an acute disease to a manageable, chronic 
condition for many patients and communities (see Figure 4). Access to HIV 
treatment in sub-Saharan Africa looks completely different than it did 15 years 
ago because of political will and financial resources leveraged by international 
partners and national governments (Steinbrook 2007). 
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Figure 4. Percentage of People Living with HIV Who Are Receiving AVR 
Therapy in Sub-Sahara Africa, 2009–2012
Source: UNAIDS 2012, 2013a, and 2013b
LESSONS FROM HIV/AIDS 
A lthough its many successes are well known throughout international health circles, the HIV/AIDS response in sub-Saharan Africa also highlights the ruinous consequences of inaction and inefficiencies in 
development approaches and advocacy. As with HIV/AIDS and other infectious 
diseases like Ebola, an insufficient response to cancer in the developing 
world will result in widespread preventable death and suffering in countries 
throughout sub-Saharan Africa (Mills and Ford 2012). Thus, a look at how the 
HIV/AIDS movement overcame an initial lack of urgency and emerged as a 
priority issue in global health offers important lessons for the future of cancer in 
the developing world. 
The Importance of Advocacy, Funding, and Coalition Building
One of the most meaningful lessons from the international AIDS response is the 
importance of broad participation and coalition building around a global call to 
action. As a result of a unifying commitment like the Millennium Development 
Goals agenda and through the leadership of centralizing organizations such 
as the Global Fund and UNAIDS, international HIV/AIDS advocacy was able 
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to build an impressive multi-stakeholder effort that helped to address various 
aspects of the epidemic (Farmer et al. 2010). The MDGs were designed to be 
simple, easy to communicate, and measurable, and as a result, have become a 
rallying cry for the global health and development community (Global Thematic 
Consultation on Health 2013). 
Since the formation of the MDGs, the international community has successfully 
framed HIV/AIDS as a broader issue critical to international security, economic 
sustainability, and human rights (Lamptey and Dirks 2012); this approach has 
significantly broadened support for HIV/AIDS in terms of both high-level political 
backing and bilateral aid commitments (Woodling, Williams, and Rushton 2012). 
In the same vein, a focus on social issues related to the epidemic — including 
the rights of poor and marginalized communities and the ethical imperative to 
broaden access to antiretroviral medication — has captured the attention and 
commitment of human rights agencies, international NGOs, and community-based 
organizations throughout sub-Saharan Africa (Lamptey and Dirks 2012). Support 
across bilateral, multilateral, private 
sector, and civil society actors has 
fueled a sizeable international 
advocacy movement which has 
contributed to the success of HIV/
AIDS programming and technical 
assistance across the developing 
world (Narayan et al. 2011, Goosby, Von Zinkernagel, et al. 2012). 
HIV/AIDS also provides an instructive example of a remarkable funding success 
in global health. In just a few years, HIV/AIDS has become one of the most 
well-funded health issues of all time (El-Sadr, Holmes, et al. 2012). A committed 
coalition of donor partners has helped to inspire greater participation and 
responsibility in national, regional, and international settings (Lamptey et 
al. 2011). While agencies like PEPFAR and the Global Fund are certainly not 
without their critics, many have argued that centralized funding mechanisms 
like these have reshaped global health infrastructure for the better, especially in 
low-income countries (El-Sadr, Morrison, et al. 2012). 
Evidence-based Programs to Cost-Effectively Expand Access to Treatment
Organizations and advocates central to the international HIV/AIDS response 
have continually placed emphasis on evidence-based approaches (Achmat 2006). 
Through these efforts, the HIV/AIDS movement has highlighted the importance 
of data in driving policy and advocacy decisions — both in terms of quantifying 
HIV/AIDS also provides an 
instructive example of a remarkable 
funding success in global health.
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the imperative for a strong public health response for communities in need, and 
in demonstrating the feasibility of sustainable solutions in low-resource settings 
(Broder 2010). Although there have been a slew of missteps since the broader 
implementation of HIV/AIDs programming in sub-Saharan Africa, the HIV/
AIDS movement should also be lauded for the development of tested service 
delivery strategies. For instance, task shifting interventions focused on training 
nurses to include higher-level medical tasks into their workload have been highly 
effective in addressing gaps in medical care across a variety of disease programs, 
especially in low-income regions with an insufficient health workforce (Oti 
2012). Similarly, numerous HIV/AIDS initiatives have been built on successful 
community-based strategies, using trained community health workers to 
provide patients with better access to prevention, screening, and follow up 
services necessary for consistent chronic care (El-Sadr, Holmes, et al. 2012). 
The HIV/AIDS movement is also well known for changing the face of drug 
delivery in low- and middle-income countries where the prohibitive cost of 
necessary antiretroviral medications stood squarely in the way of access to care 
(El Sadr, Holmes, et al. 2012). Generics have become a key strategy to cost-
effectively improve access to HIV medicines — by offering generic medications 
at a fraction of the cost of first-line therapy, national governments and aid 
agencies are able to reach many more patients worldwide and save hundreds 
of millions of dollars (Holmes et al. 2010). In particular, India has emerged as 
a major supplier to the generics industry, contributing more than 80 percent 
of antiretroviral medications to countries in sub-Saharan Africa, significantly 
improving global health, research, and development infrastructure on both 
continents (Steinbrook 2007). Due to facilitative policies targeted at reducing 
intellectual property law barriers for companies producing generic medications 
as well as expanding licensing options for low- and middle-income countries 
looking to improve access to medicines for their patients, the cost of the 
recommended first-line antiretroviral therapy for HIV has been reduced by 
nearly 99 percent from 2000 to 2010 (Hoen et al. 2011). Over the course of the 
epidemic, organizations like Médecins Sans Frontières (MSF) have observed 
these dramatic reductions in generic HIV medications (Figure 5), and have 
continued to advocate for pharmaceutical policies that encourage increased 
global access to antiretroviral therapy (MSF 2011). 
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Figure 5. Fall in Price of First-line ARV Medicines, 2000-2011 (in USD)
Source: Médecins Sans Frontières, 2011.  
*2000 graphic not to scale. 
The global HIV/AIDS movement has also successfully propelled innovative 
research and development collaborations, such as patent pools, to further 
enable access to essential medicines in low-income countries. For instance, 
the Medicines Patent Pool is a well-known example of innovative research 
infrastructure (Childs 2010). Sponsored by UNITAID and other international 
partners, the Medicines Patent Pool offers voluntary licensing agreements for 
first-line HIV medications to developing world manufacturers in exchange for 
royalties paid to patent holders in the pool (Hoen et al. 2011). These agreements 
greatly reduce the cost of medications and as of 2012, the Medicines Patent Pool 
has expanded access for 71 HIV/AIDs related patents to 78 low- and middle-
income countries across the world (Medicines Patent Pool 2012).
Finally, through research and impact evaluation, the HIV/AIDS movement 
has demonstrated that improving access to treatment in low- and middle-
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income countries entails much more than policies that merely lower the cost 
of medications. Import taxes, procurement and distribution inefficiencies, 
poor quality assurance, and bureaucratic delays in many countries continue to 
impede access to HIV treatment, despite the availability of lower-cost therapies 
(Steinbrook 2007, Knaul et al. 2010). Over the last 10-15 years, global actors 
have observed that there is no single solution to improving the availability of 
care; while pharmaceutical policies that allow for increased access to medicines 
in low-income countries are important, improved health infrastructure, 
robust care delivery systems, and financial commitments from both national 
governments and aid agencies are as essential (Selemogo 2005). Thus, improved 
treatment delivery is possible but requires broad, flexible, and far-reaching 
funding and capacity-building efforts across a variety of institutions and actors. 
BUILDING A GLOBAL CANCER MOVEMENT
Throughout the last 15 years, the international HIV/AIDS response in low-resource settings has stressed the importance of collaboration, innovation, and capacity building at all levels, from supply chain 
logistics to service delivery strategies to financing. While some progress has 
been made towards highlighting cancer and non-communicable diseases as an 
emerging policy priority in low-income countries, the global cancer community 
still has a long road ahead. Cancer funding is currently far behind trends in 
disease burden, and access to essential cancer therapies is severely lacking in 
many countries throughout sub-Saharan Africa. These shortfalls in providing 
care to cancer patients worldwide must, and can, be addressed. 
In recent years, non-communicable diseases, such as cancer, have started to 
enter policy discussions in international health. Similar to HIV/AIDS in the 
2000s, the NCD movement has been galvanized by a call to action raised at 
a 2011 United Nations Special Session on the emerging threat of NCDs in 
low- and middle-income countries, marking only the second time the UN 
General Assembly has convened on an emergency health issue in its history 
(NCD Alliance 2012). Since then, various organizations have arisen as leading 
voices in the international cancer community. Most markedly, UN-sponsored 
organizations promoting cancer efforts consist of the International Union for 
Cancer Control (UICC), International Agency for Research on Cancer (IARC), the 
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International Atomic Energy Agency (IAEA), and World Health Organization 
(WHO)-led initiatives such as the Framework Convention on Tobacco Control 
(FCTC) and the Global Strategy on Diet, Physical Activity, and Health (WHO 
2013). In addition to multilateral agencies, other players supporting cancer 
efforts in sub-Saharan Africa include academic partners, NGOs, and country-led 
initiatives. These actors range the gamut, from national research institutions 
such as the U.S. National Cancer Institute (NCI), academic and professional 
consortiums such as the Global Taskforce on the Expanded Access to Cancer 
Care and Control 
(GTF.CCC) and 
Global Oncology, Inc. 
(GO), and prominent 
university-to-university 
twinning relationships 
such as the Uganda 
Cancer Institute (UCI) 
/ Hutchinson Cancer Center Alliance at the University of Washington. Various 
U.S. non-profit institutions have also broadened their missions to incorporate 
cancer programs in low- and middle-income countries, such as the American 
Cancer Society, LIVESTRONG, Partners In Health, among others (Knaul, Frenk, 
and Shulman 2011). Countries throughout Africa have strong leadership from 
local entities as well, including ministries of health, regional initiatives such 
as the African Organization for Research and Training in Cancer (AORTIC) 
and the African Palliative Care Association (APCA), and national civil society 
organizations like the Cancer Association of South Africa (CANSA) and the 
Africa Cancer Foundation in Kenya (Morhason-Bello et al. 2013). 
Although advocacy for cancer care in low- and middle-income countries has 
started to make some headway in international development circles, these 
efforts have been piecemeal and funding has fallen far behind both current 
and future disease burdens. Unlike HIV/AIDS, there is no centralized financing 
agency for cancer or NCDs on the international stage, nor has a large-scale 
funding commitment for cancer or NCDs been proposed by governments 
and development partners (Daniels Jr., Donilon, and Bollyky 2014). Despite 
being responsible for nearly two-thirds of global disease and mortality, total 
NCD funding accounts for only 1.2 percent of all development assistance 
for health (IHME 2013). In fact, NCDs have yet to be included as an official 
funding category for the United States Agency for International Development 
(USAID) and allocations to NCDs as a whole, and especially for specific non-
Despite being responsible for nearly two-
thirds of global disease and mortality, total 
NCD funding accounts for only 1.2 percent 
of all development assistance for health.
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communicable diseases like cancer, is poorly tracked by most bilateral agencies 
(Samb et al. 2010, Wexler 2015). Even more strikingly, nearly 25 percent of all 
international assistance continues to be allocated to HIV/AIDS programs alone, 
even though HIV/AIDS is currently only responsible for 3.7 percent of global 
mortality (Woodling, Williams, and Rushton 2012). Observed in Figure 6, 
these gaps in development assistance funding (DAH) by health focus area have 
continued to widen in recent years — in 2011, while total DAH for HIV/AIDS 
was nearly $7.7 billion in U.S. dollars, NCDs, as a category, only secured a paltry 
$377 million in development assistance (IHME 2014). 
Figure 6. Development Assistance for Health (DAH) by Select Health Focus 
Area, 1990–2011
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As some experts have noted, funding patterns in international development 
tend to reflect the past and build on old expertise in infectious diseases like 
HIV/AIDS, rather than adequately evaluate and address changing conditions 
(Stuckler et al. 2008). Without key agencies willing to take on a primary funding 
role for NCDs in the developing world, organizations addressing cancer in low-
income countries have had scattered success securing funding for programs 
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in sub-Saharan Africa (Nugent and Feigl 2010). In addition, the failure of the 
international cancer community to pair commitment-based initiatives mirroring 
the MDGs, such as the WHO Global Action Plan for NCDs, to a solid funding 
infrastructure has further hindered cancer efforts in low-resource settings 
(Knaul, Frenk, and Shulman 2011). As a result, cancer and non-communicable 
diseases have been at a severe disadvantage in terms of resource mobilization 
(Kanavos 2006).
The lack of quality data on cancer incidence in low-income countries has been 
another stumbling block; such data could reinforce advocacy efforts around the 
need for cancer care and help set policy priorities that best address the disease 
burden impacting low-
income countries (Boyle 
and Levin 2008, Samb 
et al. 2010). The lack of 
rigorous research on 
cancer in the developing 
world has made it 
difficult for the global 
health community to 
develop evidence-based programs for cancer in low-resource settings throughout 
sub-Saharan Africa (Knaul, Frenk, and Shulman 2011). Some researchers and 
organizations have started to discuss the impact that cancer will have on the 
economic sustainability of low-income countries (EIU 2009, American Cancer 
Society and LIVESTRONG 2010), but arguments promoting cancer control 
and care as an international security or economic concern have yet to make a 
substantial impact in high-level policy settings (Mills and Ford 2012). Similarly, 
cancer has only recently been incorporated into discussions of health and 
human rights, despite the significant inequality of access to cancer treatment in 
low- and middle-income countries (Knaul, Frenk, and Shulman 2011). As HIV/
AIDs has demonstrated, data on disease burden, an emphasis on sustainability, 
and a rights-based dialogue inclusive of marginalized and poor populations are 
critical tools for further promoting and informing efforts in cancer control in 
low- and middle-income countries, especially in sub-Saharan Africa. 
In addition, far more work can be done to build on the success so far in adopting 
innovative HIV/AIDS strategies and pricing models to extend access to essential 
cancer medicines. As with HIV/AIDS, generics have emerged as the predominant 
strategy in ensuring access and affordability of essential cancer medicines. As of 
2014, twenty-six of the 29 cancer therapies on the essential medicines list are 
... cancer has only recently been 
incorporated into discussions of health 
and human rights, despite the significant 
inequality of access to cancer treatment 
in low- and middle-income countries.
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currently off-patent (Farmer et al. 2010). This context, as well as recent efforts 
to review and update the WHO Model List for Essential Medicines for cancers 
has further increased the potential for the promotion of access to medicines 
and cost savings through the generic industry (UICC 2015). India, as a main 
supplier of generic drugs in sub-Saharan Arica, won a groundbreaking court 
battle against Novartis in 2013, over a patent bid for the leukemia drug Imatinib 
(Chatterjee 2013). Yet, very few countries worldwide are able to take advantage 
of these developments, and most patients in sub-Saharan Africa remain unable 
to access or afford cancer therapy (Westerhaus and Castro 2006). The cancer 
community in the developing world has also not implemented innovative access 
and financing mechanisms, such as the Medicines Patent Pool or UNITAID 
(Elzawawy 2012). With proper buy-in from pharmaceutical companies and 
the generics industry in countries like India, patent pools for essential cancer 
medicines could be a promising approach to help cost-effectively address the 
rising cancer treatment burden in regions like sub-Saharan Africa. 
UNANSWERED QUESTIONS FOR THE FUTURE 
OF GLOBAL HEALTH
In many ways, the global AIDS response is an instructive example of advocacy and development that works, and the international community should continue to take a close look at how best to apply lessons learned 
from the HIV/AIDS community to cancer efforts in sub-Saharan Africa. But, 
neither the story of HIV/AIDS nor cancer are that simple. Lingering questions 
remain: Is the broad, far reaching success of the HIV/AIDS community in 
building a well-funded movement an exceptional achievement or can other 
global health issues share that momentum? Does the international HIV/AIDS 
response have to be replicated at scale for each health problem the world faces or 
are there ways to funnel advocacy to strengthen health systems more broadly? 
Most importantly, as countries face the dual challenges of infectious and chronic 
diseases in upcoming decades, what lies ahead for the future of global health? 
Many unresolved policy debates in HIV/AIDS have direct relevance to the future 
of cancer control efforts in sub-Saharan Africa and worldwide.
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Prioritizing Prevention or Treatment: Low-hanging Fruit or Long-term 
Solutions?
One such unresolved policy debate centers around the prioritization of advocacy, 
funding, and program implementation. For many years, stakeholders in the 
HIV/AIDS community have passionately drawn sides between prevention and 
treatment in low-resource settings (Goosby, Von Zinkernagel, et al. 2012). 
Proponents of preventative approaches argue that poorer countries lack the 
resources they need to treat their way out of the AIDS epidemic and a focus 
solely on treatment fails to address the underlying causes of the disease 
(Woodling, Williams, and Rushton 2012). Advocates of prioritizing treatment-
based programs contend that preventative approaches in HIV/AIDS, either 
focused on individual behavioral change or more structural issues, has only had 
limited success in halting the epidemic and that refusing to address current 
treatment needs condemns generations of patients to unnecessary suffering and 
death (Kanavos 2006). 
Despite divisive discussion, the HIV/AIDS epidemic has ultimately demonstrated 
that the answers to this debate lie somewhere between either extreme. Both 
treatment and prevention need to be included as part of a comprehensive long-
term approach to addressing the impacts of any health issue (Farmer et al. 2010). 
Many successful HIV/AIDS initiatives have shown that prevention and treatment 
efforts should be pursued in concert — prevention mitigates the underlying 
factors behind the epidemic and reduces the cost of treatment, while access to 
treatment allows current and future patients to receive care and enables more 
effective prevention (Knaul, Frenk, and Shulman 2011). 
Cancer efforts in low- and middle-income countries to date have arguably been 
heavily skewed towards prevention. In the WHO Global Action Plan for the 
Prevention and Control of NCDs (Figure 7) — the most rallying international 
policy commitment made thus far for NCDs — eight of the nine voluntary targets 
focus almost exclusively on prevention of lifestyle risk factors, while only one 
target discusses increasing the availability of affordable essential medicines for 
diseases such as cancer (WHO 2013). For the most part, international agencies 
have followed the WHO Global Action Plan’s focus on prevention and lifestyle 
risk factors as the key strategy to reduce the global NCD burden (Ngoma 2006). 
The WHO Framework Convention on Tobacco Control (FCTC), for instance, is a 
notable international covenant promoting anti-tobacco policies signed by 168 
countries worldwide (Maher and Ford 2011). The FCTC model has been promoted 
broadly across the UN agencies, and similar international initiatives targeting 
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diet and physical activity have arisen in recent years as well (WHO 2013). The 
World Cancer Declaration promoted by the UICC has adopted a more inclusive 
health systems approach, incorporating capacity building, data and registries, 
community education, diagnosis and treatment, and pain control into its target 
setting priorities, but global funding and programmatic efforts have yet to match 
these more expansive aspirations (Adams et al. 2011, UICC 2013). 
Figure 7. WHO Global Action Plan Voluntary Targets, 2013-2030 
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Source: WHO 2013
For many cancers, especially those more difficult to treat, prevention and early 
detection initiatives are undoubtedly the most cost-effective interventions at 
a population level, if targeted at the diverse range of cancers present in low-
income countries, beyond merely the control of lifestyle risk factors. Large 
scale efforts to provide HPV and hepatitis B vaccinations, for instance, are 
comparatively low-cost solutions that could dramatically reduce the incidence 
of infection-related cancers, currently a key component of the cancer burden 
in sub-Saharan Africa (Institute of Medicine 2007, Jemal et al. 2014). Tobacco 
and alcohol use, leading risk factors for a variety of cancers, can be reduced 
through national, profit-generating policies such as sales and import taxes 
(Maher and Ford 2011). For cervical cancer, “see and treat” programs that 
Cancer in Sub-Saharan Africa: The Need for New Paradigms in Global Health 23
incorporate visual inspection methods using vinegar and cryogenic removal 
of cancer cells is another cost-effective strategy that has become a standard of 
care in many low- and middle-income countries (Sahasrabuddhe et al. 2012). 
In breast cancer, early detection and screening programs have been a key focus 
for improving outcomes for patients with early-stage diagnoses (Brown et al. 
2006). For some cancer types such as lung, prostate, colorectal, and breast where 
treatment is particularly difficult and expensive, palliative care remains the 
most feasible option available, especially for patients presenting with late stage 
diagnoses (Vento 2013). Although many regulatory barriers exist, pain control 
medications are inexpensive and successful palliative care efforts in countries 
like Uganda have received global attention, inspiring organizations such as the 
American Cancer Society to incorporate “Treat the Pain” initiatives as a primary 
policy objective in their international aid portfolio (Jagwe and Merriman 2007, 
American Cancer Society 2011). 
In all of these cases, players throughout the global cancer community have 
chosen to prioritize and devote resources to cost-effective “low-hanging fruit” 
interventions, which constitute an essential first step to reducing cancer rates 
worldwide (Daniels Jr., Donilon, and Bollyky 2014). Through these efforts, 
advocates have started to dispel the myth that cancer is too complicated or 
expensive to address in low-income countries, convincing the international 
community that low-cost, effective interventions are currently available at 
a population level (Brown et al. 2006, Jemal et al. 2014, Knaul, Frenk, and 
Shulman 2011). 
However, even if prevention efforts expand successfully and begin to reduce 
rates of cancer in low-resource settings like sub-Saharan Africa, a considerable 
number of patients who currently lack access to sufficient care will still be 
diagnosed with treatable cancers over the course of their lifetime (Farmer et 
al. 2010). This inequity in access to care has resulted in mortality-to-incidence 
ratios as much as 20 percent higher in low- and middle-income countries as 
compared to wealthier regions (Jemal et al. 2014). Expanding wider access to 
cancer treatment requires a much more complex web of resources, including 
affordable therapy across various modalities, treatment delivery capacity, 
equipment, and a trained health workforce (Knaul, Frenk, and Shulman 2011). 
As a result, cancer treatment has often been overlooked in agenda-setting 
discussions, especially in low-income countries. Effective cancer therapies 
exist for many of the priority cancers common in sub-Saharan Africa, and 
extensive work remains to be done to make these care options more accessible 
to patients throughout the region (Kanavos 2006). While prevention, screening, 
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and palliative care efforts are an essential strategy to reduce the global cancer 
burden, increased investment in health systems and access to medicines policy 
cannot be ignored.
Beyond medicines alone, effective health systems are critical to improving 
treatment access, as cancer care requires highly trained medical professionals 
and specialized care platforms to address various cancers and diverse treatment 
modalities such as radiation and surgery (Oti 2012, Kingham et al. 2013). In 
sub-Saharan Africa, however, human resource capacity in cancer is abysmally 
low — many countries have as few as one pathologist or one medical oncologist 
per one million population (Figure 8), if any at all (Jemal et al. 2014). With more 
specialized modalities like radiation, access to care can be even more limited. 
Despite estimates that radiation can be beneficial in approximately 60 percent of 
diagnosed cancers, only 18 percent of the global population currently has access 
to radiation services, another inequity that is particularly stark in sub-Saharan 
Africa and south Asia (Jemal et al. 2014). 
Figure 8. Population per One Pathologist in Sub-Saharan Africa, 2012
Source: The Cancer Atlas, Second Edition (American Cancer Society 2014)  
Reprinted by the permission of the American Cancer Society, Inc. All rights reserved
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As HIV/AIDS has clearly demonstrated, the dichotomy between prevention 
and treatment presents a false choice. Sustainable solutions for prevention and 
treatment of cancer in low- and middle-income countries are sorely needed, and 
it is essential that the world take actions to achieve a comprehensive, sustainable 
approach to global cancer control for the longer-range future of sub-Saharan Africa. 
Future of Global NCDs: Disease-specific Funding or Integrated Approaches? 
The highly successful disease-specific approach taken by the HIV/AIDS 
community provides hope for any global health issue previously written off as 
too challenging (Tan, Upshur, and Ford 2003). At the same time, in promoting 
the emerging HIV/AIDS epidemic as an exceptional health issue requiring a 
targeted international response, HIV/AIDS efforts have contributed significantly 
to the “siloing” of health agendas into vertical, single disease programs (Lamptey 
et al. 2011). The discussion regarding vertical and horizontal approaches to 
health financing and program implementation is another debate that has 
fervently divided the global health community. While HIV/AIDS presently sits 
at the center of this discussion, the policy and funding directions international 
development agencies choose to take in coming years will have considerable 
impacts on cancer efforts in low- and middle-income countries worldwide. 
Proponents of vertical approaches argue that disease-specific responses have 
been particularly effective in curbing the rapid spread of epidemics such as HIV/
AIDS and Ebola, as well as instrumental in raising widespread awareness of 
critical, targeted health problems across the international community (Mills 
and Ford 2012). Critics of vertical funding approaches, however, argue that 
rather than strengthening international health as a whole, single disease efforts 
have impeded an integrated approach to health systems, disease, and poverty 
at the country level (Nugent and Feigl 2010). As a result, vertical programs have 
created unnecessary competition among disease priorities and have diverted 
funding, resources, and advocacy from achieving broader health system 
objectives (Shiffman 2008, Lamptey and Dirks 2012). 
Rather than channeling funding into specific disease programs, horizontal 
approaches to funding emphasize the importance of comprehensive health 
systems strengthening. This approach acknowledges that most low-income 
countries cannot afford to address all diseases in entirely separate siloes, especially 
at the level of vertical funding and technical support that has been expected 
for HIV/AIDS (Nigatu 2012). This is especially true for NCDs and cancer, as the 
number of separate diseases and cancers under the auspices of the NCD response 
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necessitate prevention and treatment initiatives that cut across a multitude of risk 
factors and medical specialties (Bukhman and Kidder 2011, Oti 2012). Focusing 
on expanding the capacity of health systems in low-income countries and training 
medical personnel comprehensively across multiple disease groups can improve 
health outcomes and mortality across the board (Bukhman and Kidder 2011, 
Samb et al. 2010). In doing so, however, many experts have expressed concern 
that purely horizontal approaches in low-income countries will spread funding 
and expertise too thin across health priorities and could undermine disease-
specific program effectiveness, allowing room for both communicable and non-
communicable diseases to spread unchecked (Mills and Ford 2012). 
Funding and advocacy needs for cancer reveal the tensions between these 
differing approaches. Like nearly any neglected global health issue, cancer efforts 
in sub-Saharan Africa would benefit considerably from a strong single-disease 
approach that could achieve the funding and advocacy successes of the global 
HIV/AIDS response. At the same time, cancer shows why a broader health 
systems approach is needed. In particular, cancer care in low- and middle-
income countries will require a comprehensive response and robust health 
systems that span prevention, early screening and detection services, surgery 
and radiation capabilities, drug delivery, patient support, and palliative care, 
across various cancers (Farmer et al. 2010). However, in advocating for a more 
comprehensive health systems approach in the face of funding constraints and 
competing disease priorities in global health, will cancer get lost in the shuffle?
As with the prevention versus treatment debate, the answers regarding 
vertical and horizontal approaches to funding and program implementation 
likely lies somewhere in the middle. The diagonal approach, recently coined 
by development experts, strikes a middle ground between the horizontal and 
vertical funding dichotomy (Farmer et al. 2010). Diagonal funding approaches 
aim to leverage successful disease-specific programs like the HIV/AIDS 
movement as an avenue to improve health systems and broaden support for 
health and development as a whole (Ooms et al. 2008). More simply, diagonal 
funding advocates are proposing integration across existing health platforms. 
While the international development community would be unwise to dismantle 
successful disease-specific programs, funding and advocacy momentum from 
strong vertical programs can be used to benefit a wider set of diseases and 
health issues (Rabkin and Nishtar 2011). For instance, many organizations 
have achieved benefits from combining disease efforts in HIV and tuberculosis, 
and have successfully incorporated HIV screening and prevention efforts into 
maternal and child health programs (Atun et al. 2013). 
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When asked in 2007 to consider the role of NCDs such as cancer in national 
health budgets, African health ministers emphasized the need for integrating 
across health programs at the national level (Kerr, Milburn, and Arbuthnott 
2007). The diagonal approach advocated by African policymakers might be the 
best way to conceptualize development strategy in resource-limited countries 
struggling with the control of both communicable and non-communicable 
diseases. By promoting an integrated, health systems strengthening agenda 
through incorporating disease-specific cancer control strategies onto existing 
health platforms and priorities, efforts to provide cancer care in low- and 
middle-income countries could become more feasible (Beaglehole, Bonita, and 
Magnusson 2011). Realistically, cancer-specific funding could be funneled into 
integrated care and capacity-building programs in a variety of ways, as shown 
in Table 2. For instance, HPV vaccination initiatives could be rolled out with 
existing maternal and child health infrastructure; cancer screening services 
Table 2. Examples of Ways to Leverage Existing Platforms to Support 
Cancer Prevention and Treatment in Low- and Middle-income Countries 
CANCER EXISTING HEALTH 
PLATFORM
INTERVENTION
Cervical Maternal & 
Child Health
HPV vaccination coverage targeted at girls and 
young mothers
Liver Infectious 
Diseases
Hepatitis B and Hepatitis C vaccination 
coverage
Breast, 
prostate
HIV/AIDS, 
NCDs
Early detection and screening programs, 
combined with screening for other priority 
diseases (HIV, diabetes, hypertension)
Kaposi’s 
sarcoma, 
lymphomas
HIV/AIDS Screening and referral, follow-up services
Various 
cancers
HIV/AIDS Palliative care and pain relief services
Various 
cancers
Human 
Resources  
for Health, 
Primary Care
Nurse and community health worker training in 
cancer protocols and follow-up care
Various 
cancers
Emergency Care Surgical training for priority cancers
Sources: Bukhman and Kidder 2011, Daniels Jr., Donilon, and Bollky 2014, Jemal et al. 2014, Rabkin 
and Nishtar 2011
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could be paired with community health efforts providing screening for HIV, 
diabetes, or hypertension; and existing nurse training, surgical care specialties, 
and community health worker training efforts could be expanded to include 
protocols and training in cancer care (Bukhman and Kidder 2011, Daniels Jr., 
Donilon, and Bollyky 2014, Jemal et al. 2014, Rabkin and Nishtar 2011). 
Increased levels of funding and advocacy are sorely needed for cancer in sub-
Saharan Africa. Although the global HIV/AIDS response has been a remarkable 
example of funding success over the last 15 years, it is unclear whether we can 
expect an entirely separate disease response to emerge fully funded for non-
communicable health threats like cancer in a difficult economic climate. Yet, 
these severe funding inequities in global cancer and NCDs must be addressed.
In addition to advocating for a much-needed increase in funding for NCDs in 
low-income countries, the international cancer community should continue to 
explore ways to achieve high service coverage for cancer through integrated care 
delivery programs and leveraging existing infrastructure and funding streams. 
Issues of Feasibility, Sustainability, and Power in Expanding Access to 
Cancer Care
HIV/AIDS has helped provide a potential trajectory for expanding access to 
cancer treatment worldwide. However, HIV/AIDS has seemingly emerged as a 
cause célèbre, with far less having been achieved to improve access to medicines 
for other diseases like cancer (Van Puymbroeck 2010). Considering the emerging 
threat of NCDs in sub-Saharan Africa, the success of HIV/AIDS treatment 
rollout efforts should not remain an anomaly. Provided similar voices stand up 
in protest of the current lack of access to cancer treatment in low- and middle-
income countries, unanswered questions regarding power, political will, and the 
feasibility of treatment delivery are important to keep in mind for the future of 
cancer therapy in low-resource settings.
Treating cancers in low- and middle-income countries is arguably much more 
complex than the existing model of antiretroviral rollout facilitated by global 
partners to address HIV/AIDS. As a set of diverse diseases, cancers common 
in sub-Saharan Africa call for a variety of medicines and chemotherapies to 
be included on the essential medicines list (Knaul, Frenk, and Shulman 2011). 
Chemotherapy, as a form of treatment, is also more medically demanding 
to administer than antiretroviral therapy for HIV. Chemotherapy requires 
functioning clinical facilities or options for home-based care, trained staff to 
administer treatment and monitor patients, and follow-up services throughout 
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the care process (Sikora et al. 1999). In addition to improving access to 
chemotherapy drugs, successful care for many of the priority cancers in sub-
Saharan Africa often relies on additional treatment modalities such as surgery 
and radiation (Mattke et al. 2011). Although improving access to essential 
cancer medicines is an important step to improve cancer care in sub-Saharan 
Africa, adequately addressing cancer in low- and middle-income countries will 
demand more resources and policy change than HIV/AIDS. 
The cancer community in low-income countries does have at least one strategic 
advantage — cancer affects far more patients in rich countries than HIV (El-
Sadr, Morrison, et al. 2012). With a high demand for essential and novel cancer 
therapies in more affluent 
countries, pharmaceutical 
companies are generally 
ensured payback on research, 
development, and marketing 
of cancer drugs, and as a 
result, investment in generic 
manufacturing and lower-
cost treatment solutions in low-income countries could seemingly be a less 
controversial proposition for the industry (Outterson 2013). In addition, many 
countries in sub-Saharan Africa are starting to be targeted as emerging markets 
for these therapies (Towse et al. 2011). To date, the cancer community has been 
successful in reviewing and securing essential medicine status for a number of 
important therapies, and India’s victory in the Gleevec decision may stand as an 
indicator of encouraging progress to come for access to cancer medicines in low- 
and middle-income countries (Chatterjee 2013, Shulman and Torode 2014). 
Yet, very few countries worldwide are able to take advantage of international 
policies that allow generic imports and inexpensive licensing for cancer drugs. 
Low- and middle-income countries currently have compulsory licensing 
options available to them for both HIV and cancer medicines, but the process 
is complicated and a lot of political will is needed on the part of low-income 
countries to stand up to powerful pharmaceutical companies (Westerhaus and 
Castro 2006). Even in the face of public health crises, the United States and 
European countries have consistently attempted to limit the use of compulsory 
licensing and further weaken the bargaining power of poorer countries 
(Westerhaus and Castro 2006); this is evident especially in recent trade 
agreements being brokered with countries in the Pacific, which have attempted 
… very few countries worldwide are 
taking advantage of international 
policies that allow generic imports and 
inexpensive licensing for cancer drugs.
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to further solidify wealthier countries’ restrictive intellectual policy provisions 
(MSF Canada 2013, Thow et al. 2014). Unfortunately, global trade agreements 
have often sustained the gap in power and resources between high and low-
income countries (Van Puymbroeck 2010). It will be worth watching to see how 
the generics environment may shift for HIV, cancer, and NCDs when export 
extensions for compulsory licensing products expire in 2016, and in light of the 
recently negotiated Trans-Pacific Partnership (TPP) trade agreement (Sanjuan 
2015, MSF Canada 2013, Steinbrook 2007); significant setbacks to providing 
access to low-cost cancer therapy could have a disastrous impact on the future of 
the cancer burden in sub-Saharan Africa.
The HIV/AIDS movement has also called into question the sustainability 
of current policy solutions around expanding access to medicines. As the 
nature of the HIV/AIDS epidemic has changed in recent years, so have the 
expectations and responsibilities of governments and the development 
community (Woodling, Williams, and Rushton 2012). Since institutional 
leaders in global health have committed to providing access to affordable HIV 
treatment worldwide, these efforts need to be sustainable in the long-term 
(Maher, Ford, and Unwin 2012). Many involved in the international HIV/AIDS 
response are expressing concern that institutions such as the Global Fund 
have showed signs of donor fatigue, with a decline in funding commitments in 
recent years (Hoen et al. 2011). With approximately 15-20 million HIV patients 
eligible for antiretroviral therapy still without access to treatment in low- and 
middle-income countries (UNAIDS 2014), questions around the sustainability 
of international commitments and country-level financing responsibilities are 
important to consider, especially in discussions around access to medicines. 
The challenges that come with expanding access to cancer treatment in low- 
and middle-income countries once again emphasize that in many cases, the 
global health community must extend beyond “low-hanging fruit” options most 
attractive to policymakers, funders, and implementing organizations, and strive 
towards effective solutions to comprehensively address gaps in care delivery. 
In an austere economic climate with substantial policy constraints regarding 
increased access to medicines, the sustainability of these efforts is not secure. 
Substantial progress remains to be achieved in both HIV/AIDS and cancer 
to ensure that affordable treatment is a long-term reality for patients in sub-
Saharan Africa and worldwide. 
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IMPLICATIONS FOR THE LONGER-RANGE 
FUTURE
Cancer currently sits at an historic crossroads for the international health community. At the end of the Millennium Development Goals era, the United Nations and the international community have recently adopted 
the Sustainable Development Goals (SDG) which will carry international 
development through 2030 (United Nations 2015, United Nations 2013). As 
with the MDGs, the post-2015 agenda will have a critical impact on the future 
of cancer and non-communicable diseases in low- and middle-income countries 
worldwide (Alleyne et al. 2013). As the UN SDG negotiations have progressed, 
cancer and NCDs have been placed squarely on the agenda, and institutional 
efforts defining 
the next 15 years 
of international 
development 
policy is placing 
more emphasis on 
stronger integrated 
health systems 
necessary for a comprehensive cancer care approach in low- and middle-income 
countries (United Nations 2013). Cancer in low-resource settings is beginning 
to be spotlighted as a critical policy issue for the international community, and 
encouraging developments are occurring in terms of the protection of essential 
cancer medicines in the generics industry. 
While these are all promising signs for the elevation of cancer as a policy 
priority in low- and middle-income countries, an immense amount of attention, 
funding, and institutional support is urgently required to scale-up both cancer 
prevention and treatment efforts, and reduce the number of cancer patients 
globally that needlessly fall to illness and death. Undoubtedly, cancer in low- 
and middle-income countries will also compel policy makers to grapple with 
a series of important questions related to the longer-range future of health 
and development in sub-Saharan Africa. The international community will 
need to thoughtfully consider priorities across a breadth of issues, including 
population-based prevention programs, health system capacity-building efforts, 
pharmaceutical policy, development of financing mechanisms and research 
infrastructure, and sustaining multi-stakeholder collaborations across care 
delivery platforms. Even more importantly, the many actors in global health will 
... the many actors in global health will once 
again be tested on our ability to extend beyond 
cost-effective “low-hanging fruit” solutions 
and on our willingness to commit to long-term 
prevention and care delivery efforts...
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once again be tested on our ability to extend beyond cost-effective “low-hanging 
fruit” solutions and on our willingness to commit to long-term prevention 
and care delivery efforts that will more sustainably and equitably address the 
neglected cancer burden in sub-Saharan Africa. 
The challenges ahead of us are complex and demanding but we cannot shy away 
from the longer-range implications of the cancer threat on the sustainability of 
communities throughout sub-Saharan Africa. In the wake of an intensifying 
burden of cancer and chronic diseases in low- and middle-income countries 
worldwide, new paradigms and policy solutions will need to be forged in 
global health and development. In addressing some of these questions, the 
international community would be wise to follow the important lessons that 
have been learned over the last 30 years of the HIV/AIDS epidemic.
In his seminal President Fellows Lecture at the World Bank in 2003, Peter Piot 
concluded: 
“The stakes are high. The agenda is clear. AIDS demands that we do business differently. 
AIDS requires more than personal behavior change. It requires institutional behavior 
change. AIDS is one the great moral causes of our time. We can save lives and reduce 
suffering. Effectively rising to the challenge will be a key test for the international 
system.” (Piot 2003)
Piot’s words continue to ring true in the post-2015 development era, both for 
alarming communicable diseases like Ebola that have quickly captured global 
public interest, as well as for non-communicable diseases like cancer which are 
more quietly taking center stage across low-income countries in sub-Saharan 
Africa and worldwide. Institutional behavior change will be required, and the 
stakes are high for many cancer patients without access to treatment and care in 
resource-limited settings. It is increasingly important that their voices are not 
lost in current and future policy planning for advocacy, funding, and treatment 
delivery in global health and development.  • 
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